Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Orlistat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNLIP known ✓ | P16233 | 1/20 | 1.00 |
| ▸ | DAGLA | Q9Y4D2 | 8/20 | 1.00 |
| ▸ | CNR1 | P21554 | 5/20 | 1.00 |
| ▸ | DAGLB | Q8NCG7 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABHD16A | O95870 | 1/20 | 1.00 |
| ▸ | LPL | P06858 | 1/20 | 1.00 |
| ▸ | LIPC | P11150 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | FASN | P49327 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 1.00 |
| ▸ | ABHD12 | Q8N2K0 | 1/20 | 1.00 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 1.00 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2622304 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| SCHEMBL4132917 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| SCHEMBL12083575 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| SCHEMBL8780147 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| SCHEMBL12083578 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| SCHEMBL9825785 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| SCHEMBL4132918 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| SCHEMBL2622298 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| Orlistat SCHEMBL22252870 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| Orlistat SCHEMBL10927327 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394813-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-10-08 | — | — | US | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
| US-20080081826-A1 | SYSTEM FOR EFFECTING WEIGHT LOSS | ABBOTT LABORATORIES | 2008-04-03 | — | — | US | disclosed |
| US-20080081826-A1 | SYSTEM FOR EFFECTING WEIGHT LOSS | ABBOTT LABORATORIES | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | PNLIP 70/4885DAGLA 2549/4885CNR1 3925/4885 |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | PNLIP 70/4885DAGLA 2549/4885CNR1 3925/4885 |
| US-20080081826-A1 | SYSTEM FOR EFFECTING WEIGHT LOSS | GIPR, MGLL, GLP1R | PNLIP 4/4885DAGLA 60/4885CNR1 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.